T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mondelez International
MDLZ
|
+$841M |
| 2 |
Liberty Global Class C
LBTYK
|
+$752M |
| 3 |
Apple
AAPL
|
+$720M |
| 4 |
Tesla
TSLA
|
+$713M |
| 5 |
NXP Semiconductors
NXPI
|
+$648M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$1.2B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.03B |
| 3 |
Gilead Sciences
GILD
|
+$917M |
| 4 |
Pfizer
PFE
|
+$901M |
| 5 |
Nike
NKE
|
+$872M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.88% |
| 2 | Consumer Discretionary | 14.86% |
| 3 | Financials | 14.2% |
| 4 | Technology | 12.51% |
| 5 | Industrials | 9.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
901
Angi Inc
ANGI
$176M
| $35.1M | 0.01% |
539,893
-66,050
| -11% | -$5.45M |
|
902
Agios Pharmaceuticals
AGIO
$2.04B
| $34.9M | 0.01% |
831,949
+600,770
| +260% | +$29.7M |
|
903
Watts Water Technologies
WTS
$12.9B
| $34.7M | 0.01% |
596,285
-17,960
| -3% | -$1.02M |
|
904
American Water Works
AWK
$26.8B
| $34.7M | 0.01% |
410,641
+3,801
| +0.9% | +$283K |
|
905
Eversource Energy
ES
$26.9B
| $34.6M | 0.01% |
577,739
+19,535
| +3% | +$1.1M |
|
906
Knowles
KN
$3.33B
| $34.5M | 0.01% |
2,525,070
+2,503,020
| +11,352% | +$34.5M |
|
|
MDVN
907
DELISTED
MEDIVATION, INC.
MDVN
| $34.3M | 0.01% |
568,370
-829
| -0.1% | -$47K |
|
908
DNOW Inc
DNOW
$3.04B
| $34.2M | 0.01% |
1,887,907
+505,248
| +37% | +$8.87M |
|
|
FRAN
909
DELISTED
Francesca's Holdings Corporation
FRAN
| $33.9M | 0.01% |
255,737
-195,075
| -43% | -$32.5M |
|
910
TriMas Corp
TRS
$1.41B
| $33.9M | 0.01% |
1,881,800
+1,220
| +0.1% | +$21.2K |
|
911
RenaissanceRe
RNR
$13.2B
| $33.8M | 0.01% |
287,914
+5,344
| +2% | +$613K |
|
|
BERY
912
DELISTED
Berry Global Group, Inc.
BERY
| $33.8M | 0.01% |
946,802
-195,705
| -17% | -$6.7M |
|
|
HAWK
913
DELISTED
Blackhawk Network Holdings, Inc. Common Stock
HAWK
| $33.7M | 0.01% |
1,007,142
-68,500
| -6% | -$2.29M |
|
914
Compass Minerals
CMP
$1.12B
| $33.7M | 0.01% |
454,125
+5,009
| +1% | +$379K |
|
|
ASEI
915
DELISTED
AMER SCIENCE & ENGR INC.
ASEI
| $33.6M | 0.01% |
899,043
-25,680
| -3% | -$792K |
|
916
Broadridge
BR
$19.3B
| $33.5M | 0.01% |
513,840
-3,994
| -0.8% | -$247K |
|
|
SQI
917
DELISTED
SCIQUEST, INC. COMMON STOCK
SQI
| $33.5M | 0.01% |
1,895,896
-9,675
| -0.5% | -$147K |
|
918
Editas Medicine
EDIT
$436M
| $33.5M | 0.01% |
1,414,116
+4,220
| +0.3% | +$142K |
|
919
Seres Therapeutics
MCRB
$47.4M
| $33.3M | 0.01% |
57,379
+9,837
| +21% | +$5.77M |
|
920
Prestige Consumer Healthcare
PBH
$2.48B
| $33.2M | 0.01% |
599,556
+34,336
| +6% | +$1.89M |
|
921
Sixth Street Specialty
TSLX
$1.79B
| $33M | 0.01% |
1,989,000
+71,352
| +4% | +$1.17M |
|
922
Fair Isaac
FICO
$22.6B
| $32.8M | 0.01% |
290,136
+24,767
| +9% | +$2.69M |
|
923
Hartford Financial Services
HIG
$37.7B
| $32.8M | 0.01% |
738,099
+4,460
| +0.6% | +$199K |
|
924
Seagate
STX
$199B
| $32.7M | 0.01% |
1,344,311
-20,244
| -1% | -$491K |
|
|
LHO
925
DELISTED
LaSalle Hotel Properties
LHO
| $32.7M | 0.01% |
1,385,197
-180,890
| -12% | -$4.28M |
|
Similar funds
T. Rowe Price Associates's Q2 2016 Portfolio in Review
As of Q2 2016, T. Rowe Price Associates held 2,596 positions worth $472B, up 0.75% from $468B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
T. Rowe Price Associates's Q2 2016 filing shows 95 new, 1,094 increased, 954 reduced and 84 closed positions. Its largest new stake was American Tower Corporation: 2,223,765 shares worth $246M. The largest sale was Alexion Pharmaceuticals, an estimated $1.2B.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2016 buy was American Tower Corporation: 2,223,765 shares worth $246M.
- T. Rowe Price Associates added most to Mondelez International in Q2 2016, an estimated $841M increase.
- T. Rowe Price Associates's biggest Q2 2016 reduction was Alexion Pharmaceuticals, cutting an estimated $1.2B.
- T. Rowe Price Associates fully exited BAXALTA INC COM STK (DE) in Q2 2016, selling an estimated $750M.
- T. Rowe Price Associates's ten largest holdings make up 16% of its $472B portfolio in Q2 2016.
- T. Rowe Price Associates opened 95 new positions and closed 84 in Q2 2016.
- T. Rowe Price Associates's portfolio value rose 0.75% quarter-over-quarter to $472B.
Based on T. Rowe Price Associates's 13F filing for Q2 2016, filed 15 Aug 2016.